Search
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet … oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Categories: Heterocyclic Compounds with 4 or More RingsProducts: VISUDYNE FOR INJECTION 15 mg/vial, VISUDYNE 15 MG INFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZVotucalis
go.drugbank.com/drugs/DB05032InvestigationalrEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThese cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.
Sodium phosphate, monobasic, unspecified form
go.drugbank.com/drugs/DB14503ApprovedMixtures: 500mL of Blood, Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of BloodColestipol
go.drugbank.com/drugs/DB00375Approved, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces
Categories: Compounds used in a research, industrial, or household settingSynonyms: Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxiraneEpcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigationalEpcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells. … Although this regimen is effective in up to 60% of patients, patients with relapsed or refractory DLBCL have poor outcomes.
Products: Tepkinly 48 mg Enjeksiyonluk Çözelti (1 adet), Tepkinly 4 mg/0,8 ml Enjeksiyonluk Çözelti (1 adet)Brilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Brilliant blue G, Coomassie Brilliant Blue GSolifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]
Mixtures: VESOMNİ 6 MG/0.4 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 ADET, Vesomni 6 mg/0,4 mg Tabletten mit veränderter WirkstofffreisetzungProducts: VESICARE 5 MG., VESICARE 10 MG.Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigational[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.
Categories: Compounds used in a research, industrial, or household settingProducts: PLEGRIDY®94 UG SOLUCIÓN INYECTABLE., BLASTOFERON® 44 µG SOLUCIÓN INYECTABLECamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.